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Abstract
Background: Cardiovascular diseases are highly represented in multimorbidity patterns. Nevertheless, few studies
have analysed the burden of these diseases in the population with multimorbidity. The objective of this study was
to identify and describe the cardiovascular diseases among the patients with multimorbidity.
Methods: We designed a cross-sectional study in patients ≥19 years old assigned to 251 primary health care
centres in Catalonia, Spain. The main outcome was cardiovascular morbidity burden, defined as the presence of
one or more of 24 chronic cardiovascular diseases in multimorbid patients (≥2 chronic conditions). Two groups
were defined, with and without multimorbidity; the multimorbidity group was further divided into cardiovascular
and non-cardiovascular subgroups. The secondary outcomes were: modifiable major cardiovascular risk factors
(smoking, hypertension, hypercholesterolaemia, diabetes) and cardiovascular risk score (REGICOR, Registre Gironí del
Cor). Other variables analysed were: sex, age (19–24, 25–44, 45–64, 65–79, and 80+ years), number of chronic
diseases, urban setting, active toxic habits (smoking and alcohol), physical parameters and laboratory tests.
Results: A total of 1,749,710 individuals were included (mean age, 47.4 years [SD: 17.8]; 50.7 % women), of which
nearly half (46.8 %) had multimorbidity (95 % CI: 46.9–47.1). In patients with multimorbidity,, the cardiovascular
burden was 54.1 % of morbidity (95 % CI: 54.0–54.2) and the four most prevalent cardiovascular diseases were
uncomplicated hypertension (75.3 %), varicose veins of leg (20.6 %), “other” heart disease (10.5 %) and atrial
fibrillation/flutter (6.7 %). In the cardiovascular morbidity subgroup, 38.2 % had more than one cardiovascular
disease. The most prevalent duet and triplet combinations were uncomplicated hypertension & lipid disorder
(38.8 %) and uncomplicated hypertension & lipid disorder & non-insulin dependent diabetes (11.3 %), respectively.
By age groups, the same duet was the most prevalent in patients aged 45–80 years and in men aged 25–44 years.
In women aged 19–44, varicose veins of leg & anxiety disorder/anxiety was the most prevalent; in men aged 19–24,
it was uncomplicated hypertension & obesity. Patients with multimorbidity showed a higher cardiovascular risk
profile than the non-multimorbidity group.
Conclusions: More than 50 % percent of patients with multimorbidity had cardiovascular diseases, the most
frequent being hypertension. The presence of cardiovascular risk factors and the cardiovascular risk profile were
higher in the multimorbidity group than the non-multimorbidity group. Hypertension, diabetes and dyslipidaemia
constituted the most prevalent multimorbidity pattern.
Keywords: Multimorbidity, Cardiovascular morbidity, Cardiovascular risk factors, Comorbidity, Electronic health
records, Primary health care
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Background
Multimorbidity (MM), understood as the diagnosis of
two or more disease diagnoses in the same patient, will
become a major public challenge in the coming decades.
A systematic review found that the prevalence of MM
varied depending on age, and ranged from 13 % in
participants aged 18 years and older to 95 % in a popula-
tion aged 65 years and older [1]. The forecasts for 2050
indicate that the world population aged 60 years and
older is expected to total more than 2 billion in 2050
[2]; MM is likely to increase substantially, with the
consequent impact on health services [3, 4]. At the indi-
vidual level, MM represents reduced physical and mental
function, decreased quality of life, low quality of care,
increased use of health services, major complications
with treatments, and increased mortality [5]. In addition,
MM is common in primary care and treatment manage-
ment is a major burden for health care professionals [6].
Cardiovascular diseases represent 46 % of non-
communicable disease deaths worldwide [7], and are
highly represented in MM. Several recent studies have
highlighted hypertension, diabetes, obesity and coronary
heart disease as the most frequent MM diagnoses [1, 8, 9].
Furthermore, the concurrence of multiple cardiovascular
diseases is an independent predictor of prognosis in
patients with established cardiovascular disease [10].
Knowing the cardiovascular disease burden in patients
with MM and how these diseases are associated could
help clinicians to more effectively search for other diseases
when one of them is first diagnosed. It may also contrib-
ute to the design of clinical practice guidelines and the
development and management of health programs.
The purpose of this study was to describe the burden
of cardiovascular diseases in patients with MM by sex
and life-stage in a large population sample, evaluate the
cardiovascular risk factors (CVRF) and cardiovascular
risk (CVR) present a group of patients with MM, and
compare these factors with a non-MM group.
Methods
Data source and study population
A cross-sectional study of adult residents was conducted
in Catalonia, a Mediterranean region of southern Europe
with 7,434,632 inhabitants (16 % of the Spanish popula-
tion, 2010 census). In Catalonia, 358 primary health care
teams (PHCTs) comprised of general practitioners (GPs),
nurses, social workers and support personnel are assigned
by geographical area and responsible for the health care of
the population in their areas. The Catalan Health Institute
manages 274 PHCTs (76.5 %), serving a population of
4,859,725 adults; the remaining PHCTs are managed by
other providers. Primary care professionals systematically
use electronic health records (EHR) to record diagnoses,
prescriptions and other clinical information, patient
management, and administrative activities. The Catalan
Health Institute Information System for the Development
of Research in Primary Care (SIDIAP) [11] compiles
coded clinical information from the EHR system based on
data from its 274 PHCTs. A subset of SIDIAP records
meeting the highest quality criteria for clinical data
(SIDIAP-Q) includes 40 % of the SIDIAP population
(1,936,443 patients), attended by the 1,319 GPs assigned
to 251 PHCTs whose data recording scored highest in a
validated comparison process [12]. SIDIAP has been
shown to be highly representative of the general Catalan
population in terms of geography, age and sex distribu-
tion, according to the official 2010 census [12].
The study sample, was selected from the SIDIAP-Q
database, included 1,749,710 patients aged 19 years or
older, assigned to 251 PHCTs during the period of study
(1 January- 31 December 2010); 186,733 individuals were
excluded because they were younger than 19 years.
Coding of diseases
International Classification of Diseases (ICD-10) codes
were mapped to the International Classification of
Primary Care (ICPC-2e-v.4.2, available at: http://
www.kith.no/templates/kith_WebPage____1111.aspx). R
codes (symptoms, signs and abnormal clinical and
laboratory findings, not elsewhere classified) and Z
codes (factors influencing health status and contact with
health services) were excluded, resulting in 686 included
codes. Each diagnosis was then classified using O’Hal-
loran criteria for chronic disease [13]: (i) have a duration
that has lasted, or is expected to last, at least 6 months;
(ii) have a pattern of recurrence or deterioration; (iii)
have a poor prognosis and (iv) produce consequences,
or sequel, that have an impact on the individual’s quality
of life [13, 14]. All results were described by ICPC-2
codes and 146 chronic diseases were included in the
analysis.
Cardiovascular morbidity was studied in 24 selected
cardiovascular chronic diseases from chapter K of ICPC-
2, based on active diagnoses recorded in EHR as of De-
cember 31, 2010: Rheumatic fever/heart disease (K71);
Neoplasm, cardiovascular (K72); Congenital anomaly,
cardiovascular (K73); Ischaemic heart disease with an-
gina (K74); Acute myocardial infarction (K75); Ischaemic
heart disease without angina (K76); Heart failure (K77);
Atrial fibrillation/flutter (K78); Paroxysmal tachycardia
(K79); Cardiac arrhythmia NOS (K80); Heart/arterial
murmur NOS (K81); Pulmonary heart disease (K82);
Heart valve disease NOS (K83); Heart disease, other
(K84); Hypertension, uncomplicated (K86); Hyperten-
sion, complicated (K87); Postural hypotension (K88);
Transient cerebral ischaemia (K89); Stroke/cerebrovas-
cular accident (K90); Cerebrovascular disease (K91);
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Atherosclerosis/peripheral vascular disease (K92); Pul-
monary embolism (K93); Phlebitis/thrombophlebitis
(K94) and Varicose veins of leg (K95).
Outcomes and variables
The main outcome was cardiovascular morbidity burden
defined as the coexistence of one or more chronic car-
diovascular diseases in patients with MM. MM was
defined as the coexistence of 2 or more chronic diseases.
Two study groups were defined, with and without MM.
The MM group was further divided into subgroups, con-
stituting a cardiovascular morbidity group (MM-CMG) –
i.e., MM patients with one or more chronic cardiovascular
disease– and non-cardiovascular morbidity group with
other chronic diseases (MM-NCMG).
Secondary outcomes included CVR and CVRF profile.
CVR was assessed by the REGICOR (Registre Gironí del
Cor) score, which evaluates the 10-year risk of a coron-
ary event (angina, myocardial infarct with/without
symptoms, fatal or non-fatal), with four categories of
severity: low, <5 %; moderate, 5–9.9 %; high, 10–14.9 %;
and very high, ≥ 15 % [15]. This score is only applicable
to individuals aged 35 to 74 years.
Modifiable major CVRFs registered in the EHR and
the sum of these major factors were analysed: smoking,
hypertension, hypercholesterolaemia and diabetes. Other
CVRFs evaluated were: hypertriglyceridaemia, obesity,
and alcoholism (in average units of weekly consumption,
classified as: low risk consumption [17–28 units in men
and 11–17 units in women]; risky consumption [>28
and > 17, respectively]) [16, 17]. Five additional variables
were considered in the analysis: sex (female/male), age
(years), age groups (19–24, 25–44, 45–64, 65–79, and 80
+ years), number of chronic diseases and setting (urban/
rural). Physical examinations yielded values for body
mass index (BMI, kg/cm2) and blood pressure (mm Hg)
and included laboratory tests: glycated haemoglobin (%),
creatinine (mg/dl), uric acid (mg/dl), total cholesterol
(mg/dl) and triglycerides (mg/dl), along with glomerular
filtration rate < 60 ml/min/1.73 m2 to determine a
decrease in renal function [18].
Statistical analysis
Descriptive statistics were used to summarize overall in-
formation. Categorical variables were expressed as fre-
quencies (percentage) and continuous as mean
(Standard deviation, SD) or median (interquartile range,
IQR). The MM crude prevalence and 95 % confidence
intervals (CI) were calculated. The differences between
MM and non-MM groups were tested using Student t,
Mann–Whitney or Chi-square for unadjusted compari-
son, as appropriate. The crude prevalence (95 % CI) of
MM-CMG was calculated. Prevalence estimates of each
CV chronic condition and 95 % CI were obtained. The
95 % CI for the prevalences was calculated using the
continuity-corrected Wilson score interval.
For comparison of MM-CMG, MM-NCMG and non-
MM groups, ANOVA, Kruskal-Wallis or Chi square
tests were used as appropriate. To determine the most
prevalent MM patterns in MM-CMG, all possible com-
binations of each CV disease, one and two chronic
conditions and their frequencies were calculated for each
sex and age group. CVR score (REGICOR) distribution
was compared within the three groups studied..We
assumed that missing data were missing completely at
random (MCAR), and so we performed a complete case
analysis to handle missing data. We had sufficient power
for our analysis, even though we lost part of our data
set.
Spearman correlation between number of chronic
diseases and chronic cardiovascular diseases and age was
assessed.
All statistical tests were two-sided at the 5 % signifi-
cance level. The analyses were performed using SPSS for
Windows, version 18 and R version 3.2.3.
Results
A total of 1,749,710 individuals ≥19 years old were in-
cluded in the study (Fig. 1). The mean age of the sample
was 47.4 years (SD: 17.8) and 50.7 % were women.
Nearly half of the total cohort (46.8 %, 95 % CI: 46.7–
48.1) met MM criteria. Descriptive characteristics of pa-
tients in the MM group (including both the MM-CMG
and MM-NCMG) and the non-MM group are shown in
Table 1. For all variables, significant differences were
found between the three study groups (Table 1).
MM prevalence increased with age group (19–24, 25–
44, 45–64, 65–79, and 80 or more years), as follows:
15.9 % (95 % CI: 15.7–16.1), 24.3 % (95 % CI: 24.2–24.4),
58.7 % (95 % CI:58.6–58.9), 88.7 % (95 % CI: 88.6–88.8),
and 92.1 % (95 % CI: 91.9–92.2), respectively (p < 0.001).
The total MM population showed significantly higher
prevalence (p < 0.001) than the non-MM group for three
diagnsoses: hypertension (41.1 % vs. 1.8 %), hypercholes-
terolaemia (40.4 % vs. 3.2 %) and diabetes mellitus
(15.6 % vs. 0.5 %). Except for smoking (23.1 % vs. 39.0 %,
p < 0.001), the median number of CVRFs in the MM
population was 4 (IQR: 2;6) vs. 2 (IQR: 1;4) in the non-
MM group (p < 0.001). The median of major CVRFs in
patients with MM was 1 (IQR: 1;2) and 0 (IQR: 0;1) for
the non-MM group (p < 0.001) (Table 2).
The MM-CMG patients constituted 54.1 % (95 % CI:
54.0–54.2) of the total MM population (Fig. 1). MM-
CMG also increased with age group (19–24, 25–44, 45–
64, 65–79, and 80 or more years), as follows: 1.6 %
(95 % CI: 1.5–1.6), 5.0 % (95 % CI: 5.0–5.1), 29.4 %
(95 % CI: 29.3–29.5), 68.9 % (95 % CI: 68.8–69.1), and
81.6 % (95 % CI: 81.6–81.4), respectively (p < 0.001). The
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four most prevalent cardiovascular diseases were un-
complicated hypertension (75.3 %), varicose veins of the
leg (20.6 %), other heart disease (10.5 %), and atrial
fibrillation/flutter (6.7 %) (Fig. 2). In this group, 38.2 %
had more than one cardiovascular disease. Among those
patients, the most prevalent combinations were the duet
of uncomplicated hypertension & lipid disorder (38.8 %,
95 % CI: 38.7–39.0) and the triplet of uncomplicated
hypertension & lipid disorder & non-insulin-dependent
diabetes (11.3 %, 95 % CI: 11.2–11.4). By age group, the
distribution of duets was uncomplicated hypertension &
lipid disorder in all MM-CMG patients aged 45–80 years
and also in younger men, aged 25–44 years; varicose
veins of the leg & anxiety disorder/anxiety in women
aged 19–44 years and uncomplicated hypertension &
obesity in the youngest men, aged 19–24 (Table 3). The
most prevalent triplets are shown in Table 4.
Significant differences were found in CVR scores
between the MM-CMG, MM-NCMG and non-MM
groups. Both MM groups had a higher CVR than the
non-MM group (Fig. 3).
The correlations between number of chronic dis-
eases and age was 0.60 (p < 0.001) and between
number of chronic cardiovascular diseases and age
was 0.57 (p 0.001).
Discussion
Main findings
Cardiovascular diseases accounted for more than 50 %
of the burden of chronic disease in patients with MM
patients, in part due to a high prevalence of hyperten-
sion. Both CVRFs and CVR were increased in patients
with MM, compared to the non-MM population. Hyper-
tension, diabetes and dyslipidaemia constituted the most
prevalent cardiovascular-endocrine-metabolic pattern.
Strengths and limitations
The major strength of this study was the analysis of a
large, high-quality database of primary-care EHR that
has been shown to be representative of a much larger
population. Other studies have shown that more accur-
ate conclusions can be drawn from EHR data than from
survey-based datasets [19–21]. A number of potential
limitations must be taken into account as well. First,
chronic diseases could be underreported, which would
affect the the observed MM prevalence. For example,
29 % of the Catalan population, especially people with
higher socioeconomic status, buys private health insur-
ance to supplement the universal health care services,
which could affect population prevalence data. Other
variables, such as smoking habit, are under-registered in
Fig. 1 Sampling framework
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Table 1 Descriptive characteristics of patients by multimorbidity or non-multimorbidity group (1,749,710 adult patients, Catalonia, 2010)
Multimorbidity group Non-multimorbidity
group
Total
Cardiovascular
morbidity
Non-cardiovascular
morbidity
Variables (n = 442,816) (n = 375,355) (n = 931,539) (N = 1,749,710)
Age (years) 65.7 (14.6) 48.2 (15.4) 38.3 (12.7) 47.4 (17.8)
Sex (% females) 56.1 57.5 45.5 50.7
Number of chronic diseases (median, IQR) 5.0 (3.0;7.0) 3.0 (2.0;4.0) 0.0 (0.0;1.0) 1.0 (0.0;3.0)
Visits (median, IQR) 10.0 (6.0;18.0) 6.0 (3.0;11.0) 1.0 (0.0;4.0) 4.0 (1.0;9.0)
Urban setting (%) 83.4 84.0 84.2 84.0
Physical examination
BMI (kg/cm2) (n= 509,368) 29.7 (5.1) 28.0 (5.4) 26.0 (4.7) 28.3 (5.3)
Systolic BP (mm Hg) (n = 773,446) 135.2 (16.2) 126.6 (14.6) 123.8 (14.9) 129.7 (16.3)
Diastolic BP (mm Hg) (n = 774,139) 76.7 (10.3) 76.0 (9.6) 74.5 (10.1) 75.9 (10.1)
Laboratory tests
Glycated haemoglobin (%)(SD) (n = 208,581) 6.6 (1.3) 6.3 (1.5) 5.7 (1.2) 6.4 (1.4)
Creatinine (mg/dl) (SD) (n = 738,083) 0.9 (0.4) 0.8 (0.2) 0.8 (0.2) 0.9 (0.3)
Uric acid (mg/dl) (SD) (n = 475, 334) 5.5 (1.6) 4.8 (1.4) 4.8 (1.4) 5.2 (1.5)
Total cholesterol (mg/dl) (SD) (n = 745,010) 202.0 (39.7) 209.0 (40.6) 194.3 (38.4) 201.8 (40.0)
Triglycerides (mg/dl) (SD) (n = 190,159) 132.9 (82.9) 129 (98.7) 113.3 (75.7) 127.5 (86.4)
Glomerular filtration rate < 60 % (%) (n = 544,438) 17.6 3.2 1.3 9.2
p-values overall between multimorbidity and non-multimorbidity groups were significant for all variables (p < 0.001)
Table 2 Distribution of cardiovascular risk factors by multimorbidity and non-multimorbidity groups (1,749,710 adult patients,
Catalonia, 2010)
Multimorbidity group Non-multimorbidity group Total
Cardiovascular
morbidity
Non-cardiovascular
morbidity
(n = 442,816) (n = 375,355) (n = 931,539) (N = 1,749,710)
Major modifiable cardiovascular risk factors
Smoking (n = 1,329,331) 15.1 33.3 39.0 29.9
Hypertension (n = 1,749,710) 75.9 0.0 1.8 20.2
Hypercholesterolemia (n = 1,749,710) 47.7 31.8 3.2 20.6
Diabetes (n = 1,749,710) 22.8 7.1 0.5 7.6
Other factors
Hypertriglyceridemia (n = 190,159) 27.8 24.9 18.2 24.9
Obesity (n = 1,749,710) 24.5 15.5 1.8 10.5
Alcoholism (n = 577,213) 28.2 29.8 32.4 29.9
Sum of major factors (median, [IQR]) (n = 1,329,331) 2 [1;2] 1 [0;1] 0 [0;1] 1 [0;1]
Cardiovascular risk score (REGICOR) (median, [IQR]) (n = 264,773)a 4 [3;7] 3 [2;5] 2 [1;4] 4 [2;6]
Cardiovascular risk score (REGICOR) (n = 264,773)a
Low 60.6 74.6 84.5 67.4
Moderate 30.1 20.5 13.4 25.4
High 6.9 3.8 1.7 5.4
Very high 2.4 1.1 0.4 1.8
p-values overall between multimorbidity and non-multimorbidity groups were significant for all variables (p < 0.001)
aOnly individuals aged 35 to 74 years were included because REGICOR score is only applicable to these age range
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the EHR (notably in the MM-CVG, exactly the group
that should be addressed with precision on this variable),
and this may modify the final results.
On the other hand, there could be an over-
representation of chronic diagnoses (e.g., hypertension,
diabetes, hyperlipidaemia, etc.) that are included in the
goal/incentive contracts of Catalan PHCTs. Another as-
pect is the definition and counting of the chronic condi-
tions included, which could modify the results as showen
in previous studies [22, 23]. Finally, residual confounding
cannot be completely excluded; certain epidemiological
factors or other health determinants were not considered
in this study, such as environmental factors.
Comparison with existing literature
Very few studies have evaluated the cardiovascular bur-
den in MM. In a sample of 73,254 persons of all ages,
Landwehr et al. observed high comorbidity within a
group of 30 cardiovascular disorders [24]. Another more
recent study of cardiovascular diseases in patients with
MM aged ≥18 years in a primary care setting showed
that almost 60 % of the patients included had one car-
diovascular disease and 34 % had two of them. Their
study focused on ethnic differences and did not provide
data about combinations of diseases or MM patterns by
age groups [8]. Other studies have shown a high impact
of cardiovascular diseases in middle-age, resulting in in-
creased mortality risk [25, 26].
In addition, the prevalence of MM and the main pat-
terns described in different studies focused in Spain may
vary from other European countries. The number of
chronic conditions included, age ranges of the study
population and the definition of MM are the major
explanations for these differences [9, 27]. Different Span-
ish regions also have differences in MM prevalences:
47 % (ages 19+) in Catalonia [28], 37 % (15+) in Aragon
[9], and 24 % (all ages) in Basque Country [28], all from
EHR analysis, and 69 % (18+) in a representative survey
of the Spanish population [29]. These differences may be
due to the methodology used in these studies or to the
effects of socioeconomic inequalities between territorial
regions of Spain [30]. Nonetheless, cardiovascular dis-
eases are present in the main MM patterns reported in
most countries. In a recent systematic review that in-
cluded observational studies performed in primary care
settings, hypertension and osteoarthritis were the most
frequent combination, followed by other combinations
that included cardiovascular diseases [1]. Similarly, in
our study the most frequent combination was uncompli-
cated hypertension & lipid disorder.
Hypertension is the most prevalent disease related to
medical consultation by those aged 65 and older [31].
The addition to hypertension of other cardiovascular
diseases has been associated with increased morbidity
and consequently with increased costs [32]. The heavy
burden on health services indicates that cardiovascular
morbidity requires major efforts in to prevent these dis-
eases and especially a comprehensive approach to CVR
prevention and reduction [33]. Although data about car-
diovascular comorbidity are readily available, particularly
with regard to a specific index disease (hypertension,
coronary heart disease, heart failure, etc.) [34–36], pub-
lished data on cardiovascular diseases in MM are scarce.
In the primary health care setting, however, the MM
approach has been recommended as more suitable than
focusing on one specific disease [3, 37].
Fig. 2 Cardiovascular morbidity burden in adults with multimorbidity (n = 818,171) in Catalonia, 2010
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Table 3 Most prevalent comorbidities associated with cardiovascular diseases in multimorbid patients with cardiovascular morbidity, by age group and sex (442,816 adult
patients, Catalonia, 2010)
Age Groups
(years)
Female
n = 248,407
Male
n = 194,409
Cardiovascular index disease Associated disease 1 n % 95 % CI Cardiovascular index disease Associated disease 1 n % 95 % CI
19–24
n = 2,152
Varicose veins of leg Anxiety disorder/anxiety state 92 7.1 (5.8–8.7) Hypertension, uncomplicated Obesity 78 9.0 (7.2–11.2)
Postural hypotension Anxiety disorder/anxiety state 83 6.4 (5.2–8.0) Heart disease, other Acne 39 4.5 (3.3–6.2)
Hypertension, uncomplicated Obesity 35 2.7 (1.9–3.8) Postural hypotension Acne 16 1.8 (1.1–3.1)
Paroxysmal tachycardia Anxiety disorder/anxiety state 31 2.4 (1.7–3–4) Varicose veins of leg Acquired deformity of spine 16 1.8 (0.8–2.6)
Heart disease, other Anxiety disorder/anxiety state 24 1.9 (1.2–2.8) Congenital anomaly cardiovascular Acne 13 1.5 (0.8–2.6)
25–44
n = 37,308
Varicose veins of leg Anxiety disorder/anxiety state 2,794 13.0 (12.6–13.5) Hypertension, uncomplicated Lipid disorder 3,425 21.6 (21.0–22.3)
Hypertension, uncomplicated Obesity 2,125 9.9 (9.5–10.3) Varicose veins of leg Lipid disorder 476 3.0 (2.7–3.3)
Postural hypotension Anxiety disorder/anxiety state 527 2.5 (2.3–2.7) Heart disease, other Lipid disorder 451 2.8 (2.6–3.1)
Heart disease, other Anxiety disorder/anxiety state 253 1.2 (1.0–1.3) Hypertension, complicated Hypertension, uncomplicated 201 1.3 (1.1–1.5)
Paroxysmal tachycardia Anxiety disorder/anxiety state 215 1.0 (0.9–1.1) Acute myocardial infarction Lipid disorder 159 1.0 (0.9–1.2)
45–64
n = 154,049
Hypertension, uncomplicated Lipid disorder 25,930 32.5 (32.2–32.9) Hypertension, uncomplicated Lipid disorder 30,975 41.7 (41.3–42.0)
Varicose veins of leg Lipid disorder 10,339 13.0 (12.7–13.2) Heart disease, other Hypertension, uncomplicated 4,186 5.6 (5.5–5.8)
Heart disease, other Hypertension, uncomplicated 2,057 2.6 (2.5–2.7) Ischaemic heart disease w/o angina Lipid disorder 2,992 4.0 (3.9–4.2)
Heart valve disease NOS Hypertension, uncomplicated 1,131 1.4 (1.3–1.5) Varicose veins of leg Lipid disorder 2,745 3.7 (3.6–3.8)
Stroke/cerebrovascular accident Hypertension, uncomplicated 895 1.1 (1.1–1.2) Acute myocardial infarction Lipid disorder 2,582 3.5 (3.3–3.6)
65–79
n = 168,340
Hypertension, uncomplicated Lipid disorder 46,236 49.5 (49.2–49.8) Hypertension, uncomplicated Lipid disorder 32,003 42.7 (42.3–43.1)
Varicose veins of leg Hypertension, uncomplicated 16,214 17.4 (17.1–17.6) Heart disease, other Hypertension, uncomplicated 8,156 10.9 (10.7–11.1)
Heart disease, other Hypertension, uncomplicated 7,075 7.6 (7.4–7.7) Ischaemic heart disease w/o angina Hypertension, uncomplicated 5,297 7.1 6.9–7.3)
Atrial fibrillation/flutter Hypertension, uncomplicated 4,739 5.1 (4.9–5.2) Atrial fibrillation/flutter Hypertension, uncomplicated 4,765 6.4 (6.2–6.5)
Heart valve disease NOS Hypertension, uncomplicated 4,164 4.5 (4.3–4.6) Stroke/cerebrovascular accident Hypertension, uncomplicated 4,522 6.0 (5.9–6.2)
80+
n = 80,967
Hypertension, uncomplicated Lipid disorder 22,984 43.7 (43.3–44.2) Hypertension, uncomplicated Lipid disorder 9,115 32.1 (31.5–32.6)
Varicose veins of leg Hypertension, uncomplicated 8,923 17.0 (16.7–17.3) Heart disease, other Hypertension, uncomplicated 4,244 14.9 (14.5–15.4)
Atrial fibrillation/flutter Hypertension, uncomplicated 6,404 12.2 (11.9–12.5) Atrial fibrillation/flutter Hypertension, uncomplicated 3,600 12.7 (12.3–13.1)
Heart disease, other Hypertension, uncomplicated 6,022 11.5 (11.2–11.7) Stroke/cerebrovascular accident Hypertension, uncomplicated 2,651 9.3 (9.0–9.7)
Heart failure Hypertension, uncomplicated 5,814 11.1 (10.8–11.3) Heart failure Hypertension, uncomplicated 2,579 9.1 (8.7–9.4)
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Table 4 Two most prevalent comorbidity diseases associated with cardiovascular diseases in multimorbid patients with cardiovascular morbidity, by age group and sex (442,816
adult patients, Catalonia, 2010)
Age Groups
(years)
Women
n = 248,407
Men
n = 194,409
Index
cardiovascular
disease
Associated
disease 1
Associated
disease 2
n % 95 % CI Index cardiovascular
disease
Associated
disease 1
Associated
disease 2
n % 95 % CI
19–24
n = 2,152
Postural
hypotension
Acne Anxiety disorder/
anxiety state
14 1.1 (0.6–1.9) Hypertension,
uncomplicated
Obesity Acne 8 0.9 (0.4–1.9)
Varicose veins of
leg
Acne Anxiety disorder/
anxiety state
13 1.0 (0.6–1.8) Heart disease, other Dermatitis/
atopic eczema
Asthma 6 0.7 (0.3–1.6)
Hypertension,
uncomplicated
Endocrine/metabolic/
nutritional disorder, other
Obesity 9 0.7 (0.3–1.4) Congenital anomaly
cardiovascular
Asthma Heart valve disease
NOS
3 0.3 (0.1–1.1)
Heart valve
disease NOS
Acne Acne 5 0.4 (0.1–1.0) Cardiac arrhythmia
NOS
Acne Musculoskeletal
disease, other
3 0.3 (0.1–1.1)
Paroxysmal
tachycardia
Depressive disorder Anxiety disorder/
anxiety state
4 0.3 (0.1–0.9) Heart valve disease
NOS
Asthma Congenital anomaly,
cardiovascular
3 0.3 (0.1–1.1)
25–44
n = 37,308
Hypertension,
uncomplicated
Lipid disorder Obesity 538 2.5 (2.3–2.7) Hypertension,
uncomplicated
Lipid disorder Obesity 1,076 6.8 (6.4–7.2)
Varicose veins of
leg
Depressive disorder Anxiety disorder/
anxiety state
491 2.3 (2.1–2.5) Heart disease, other Lipid disorder Hypertension,
uncomplicated
138 0.9 (0.7–1.0)
Postural
hypotension
Depressive disorder Anxiety disorder/
anxiety state
102 0.5 (0.4–0.6) Varicose veins of leg Lipid disorder Obesity 105 0.7 (0.5–0.8)
Phlebitis/thrombo-
phlebitis
Obesity Varicose veins of
leg
59 0.3 (0.2–0.4) Hypertension,
complicated
Lipid disorder Hypertension,
uncomplicated
66 0.4 (0.3–0.5
Heart disease,
other
Depressive disorder Anxiety disorder/
anxiety state
46 0.2 (0.2–0–3) Acute myocardial
infarction
Lipid disorder Hypertension,
uncomplicated
60 0.4 (0.3–0.5
45–64
n = 154,049
Hypertension,
uncomplicated
Lipid disorder Obesity 9,134 11.5 (11.2–11.7) Hypertension,
uncomplicated
Lipid disorder Diabetes, non-insulin
dependent
8,631 11.6 (11.4–11.8)
Varicose veins of
leg
Lipid disorder Hypertension,
uncomplicated
3,761 4.7 (4.6–4.9) Heart disease, other Lipid disorder Hypertension,
uncomplicated
2,275 3.1 (2.9–3.2)
Heart disease,
other
Lipid disorder Hypertension,
uncomplicated
1,081 1.4 (1.3–1.4) Ischaemic heart
disease w/o angina
Lipid disorder Hypertension,
uncomplicated
1,744 2.3 (2.2–2.5)
Heart valve
disease NOS
Lipid disorder Hypertension,
uncomplicated
578 0.7 (0.7–0–8) Acute myocardial
infarction
Lipid disorder Hypertension,
uncomplicated
1,361 1.8 (1.7–1.9)
Stroke/
cerebrovascular
accident
Lipid disorder Hypertension,
uncomplicated
500 0.6 (0.6–0.7) Atherosclerosis/PVD Lipid disorder Hypertension,
uncomplicated
1,275 1.7 (1.6–1.8)
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Table 4 Two most prevalent comorbidity diseases associated with cardiovascular diseases in multimorbid patients with cardiovascular morbidity, by age group and sex (442,816
adult patients, Catalonia, 2010) (Continued)
65–79
n = 168,340
Hypertension,
uncomplicated
Lipid disorder Obesity 15,115 16.2 (15.9–16.4) Hypertension,
uncomplicated
Lipid disorder Diabetes, non-insulin
dependent
11,573 15.4 (15.2–15.7)
Varicose veins of
leg
Lipid disorder Hypertension,
uncomplicated
9,365 10.0 (9.8–10.2) Heart disease, other Lipid disorder Hypertension,
uncomplicated
4,389 5.9 (5.7–6.0)
Heart disease,
other
Lipid disorder Hypertension,
uncomplicated
4,298 4.6 (4.5–4.7) Ischaemic heart
disease w/o angina
Lipid disorder Hypertension,
uncomplicated
3,346 4.5 (4.3–4.6)
Heart valve
disease NOS
Lipid disorder Hypertension,
uncomplicated
2,530 2.7 (2.6–2.8) Atherosclerosis/PVD Lipid disorder Hypertension,
uncomplicated
2675 3.6 (3.4–3.7)
Atrial fibrillation/
flutter
Lipid disorder Hypertension,
uncomplicated
2,525 2.7 (2.6–2.8) Stroke/
cerebrovascular
accident
Lipid disorder Hypertension,
uncomplicated
2,557 3.4 (3.3–3.5)
80+
n = 80,967
Hypertension,
uncomplicated
Lipid disorder Diabetes, non-
insulin dependent
6,769 12.9 (12.6–13.2) Hypertension,
uncomplicated
Benign prostatic
hypertrophy
Lipid disorder 3658 12.9 (12.5–13.3)
Varicose veins of
leg
Lipid disorder Hypertension,
uncomplicated
4,445 8.5 (8.2–8.7) Heart disease, other Lipid disorder Hypertension,
uncomplicated
1,823 6.4 (6.1–6.7)
Heart disease,
other
Lipid disorder Hypertension,
uncomplicated
3,255 6.2 (6.0–6.4) Atrial fibrillation/
flutter
Benign prostatic
hypertrophy
Hypertension,
uncomplicated
1,466 5.2 (4.9–5.4)
Atrial fibrillation/
flutter
Lipid disorder Hypertension,
uncomplicated
2,900 5.5 (5.3–5.7) Ischaemic heart
disease w/o angina
Lipid disorder Hypertension,
uncomplicated
1,357 4.8 (4.5–5.0)
Heart failure Lipid disorder Hypertension,
uncomplicated
2,776 5.3 (5.1–5.5) Stroke/
cerebrovascular
accident
Lipid disorder Hypertension,
uncomplicated
1,153 4.1 (3.8–4.3)
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A recent literature review evaluated MM studies that
specifically analysed cardiovascular diseases, and found
that almost all were focused on an index disease (e.g.,
coronary heart disease or heart failure) or a limited
number of cardiovascular diseases [38]. Another very
recent study called for practice-based research focused
on common dyads and triads in order to translate these
results to best-practice guidelines, including disease
patterns even when the relationships between them are
not fully understood (for example, coexisting depression
and CVD) [39]. Our study, evaluated the comorbidity of
24 chronic cardiovascular diseases, focusing the atten-
tion on these diseases and providing data on the patterns
observed.
Impact of the study
The findings from this study make several contributions
to the current literature. Despite considerable knowledge
about the separate impacts of cardiovascular diseases on
the burden of chronic diseases, there is a gap in know-
ledge about their impact on MM as a whole. The
present study quantifies this impact, based on analysis of
a large, high-quality database. On the other hand, our
data provide more information about the associations
between cardiovascular diseases and MM, which may
help clinicians to understand the complexity of MM.
Our analysis of MM-CMG patterns showed a high
prevalence of certain diseases accompanying cardiovas-
cular diseases, such as lipid disorders in men aged
25 years and older and women aged 45 years and older.
This could be a useful consideration for clinicians
screening for comorbidities when a chronic disease is
first diagnosed. Another finding of clinical interest was
the association of depressive disorder and anxiety with
paroxysmal tachycardia in younger women (19–24 years)
and with heart disease in women aged 25–44 years.
When the first of these cardiovascular diagnoses is made
clinicians may be well advised to explore symptoms in
the mental health sphere.
According to the observed presentation of associated
diseases in the present study results, future studies could
investigate the chronological order of diseases and the
interventions in family practice that are most adequate
to prevent the accumulation of diseases. Another poten-
tial impact of these results would be to introduce the
concept of multimorbidity earlier in university degree
programs that prepare health professionals, changing the
disease-specific focus to a multimorbidity approach.
Finally, in the field of health policy, efforts should focus
on programs to avoid the accumulation of diseases when
one disease appears, introducing guidelines on the man-
agement of associated diseases and the use of predictive
algorithms that help doctors to identify occult diseases
based on probabilistic models.
Future research
Future research is needed to establish the optimal
approaches to prevent or avoid the patient progression
from non-MM to diagnsosis of one or more cardiovas-
cular diseases in addition to other chronic but prevent-
able diseases. In this sense, longitudinal studies should
be performed to establish the specific moment of disease
occurrence, how diseases are related over time and what
Note: All comparisons between groups had a p-value <0.001.
Low Moderate  High Very High
Fig. 3 Cardiovascular risk distribution by multimorbidity or non-multimorbidity group (264,773 adult patients aged 35–74 years, Catalonia, 2010)
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interventions can be useful to prevent the onset of co-
morbidities in various patient populations.
Conclusions
Data from a large sample of primary health care records
showed that cardiovascular diseases represent more than
half of the MM burden. Cardiovascular risk factors and
risk profiles were higher in patients with MM than in
the non-MM group, mainly due to the high prevalence
of hypertension. Hypertension, diabetes and dyslipidae-
mia constitute the most prevalent cardiovascular-
endocrine-metabolic pattern.
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